Risk for CMV reactivation in children undergoing allogeneic hematopoietic stem cell transplantation

Pediatric Blood and Cancer

Volumn 62, Issue 2, 2015, Pages 364-366

  Qayed, Muna ^a   Khurana, Monica ^b   Hilinski, Joseph ^c   Gillespie, Scott ^c   Mccracken, Courtney ^c   Applegate, Kristy ^a   Chiang, Kuang Yueh ^a   Horan, John ^d  

^a CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^b CHILDREN S HOSPITAL OAKLAND   (United States)

^c EMORY UNIVERSITY   (United States)

^d Columbia University ^*  (United States)

Author keywords

CMV; Surveillance; Transplantation

Indexed keywords

ACICLOVIR; GANCICLOVIR; STEROID;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; CHEMOPROPHYLAXIS; CHILD; CYTOMEGALOVIRUS INFECTION; DONOR; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HLA SYSTEM; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REINFECTION; UMBILICAL CORD BLOOD; VIRUS REACTIVATION; ADOLESCENT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PHYSIOLOGY; RISK FACTOR; VIRUS ACTIVATION;

ADOLESCENT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; RISK FACTORS; VIRUS ACTIVATION;

EID: 84927510043     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25237     Document Type: Article

References (11)

1. Pollack M, Heugel J, Xie H, et al. An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2011; 17:664-673.
2. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86:2815-2820.
3. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99:1159-1164.
4. Yoon HS, Lee JH, Choi ES, et al. Cytomegalovirus infection in children who underwent hematopoietic stem cell transplantation at a single center: A retrospective study of the risk factors. Pediatr Transplant 2009; 13:898-905.
5. Paris C, Kopp K, King A, et al. Cytomegalovirus infection in children undergoing hematopoietic stem cell transplantation in Chile. Pediatr Blood Cancer 2009; 53:453-458.
6. Haastrup E, Muller K, Baekgaard H, et al. Cytomegalovirus infection after allogeneic stem cell transplant in children. Pediatr Transplant 2005; 9:734-740.
7. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325:1601-1607.
8. Verdonck LF, Dekker AW, Rozenberg-Arska M, et al. A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants. Clin Infect Dis. 1997; 24:901-907.
9. Milano F, Pergam SA, Xie H, et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood 2011; 118:5689-5696.
10. Berger M, Figari O, Bruno B, et al. Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality. Bone Marrow Transplant 2008; 41:55-62.
11. Boeckh M, Stevens-Ayers T, Bowden RA. Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. J Infect Dis 1996; 174:907-912.